Background: Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

There is uncertainty regarding the effectiveness and occurrence of thromboembolic events
in patients treated with prothrombin complex concentrates (PCCs) for the management of …

Historically, most patients who required parenteral anticoagulation received heparin,
whereas those patients requiring oral anticoagulation received warfarin. Due to the narrow …

The new anticoagulants dabigatran and rivaroxaban can be responsible for haemorrhagic
complications. As for any anticoagulant, bleeding management is challenging. We aimed to …

Aims To evaluate apixaban single dose safety, tolerability, pharmacokinetics and
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …

Direct new oral anticoagulants (NOACs)–inhibitors of thrombin or factor Xa–are intended to
be used largely in the treatment of venous thromboembolic disease or the prevention of …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Oral direct inhibitors (ODIs) of thrombin and factor Xa are now approved as anticoagulant
drugs. The first two drugs to complete phase III clinical trials for thromboprophylaxis in …